|
|
Article: Cobalis Corp. PreHistin(TM) Significantly Reduces Allergy Symptoms in 714 Patient Phase 3 Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- October 27, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Safe, Non-Drowsy PreHistin(TM) Achieves Clinical and Statistical Significance (p= 0.0028) Versus Placebo; Study Demonstrates Dramatic Reduction in Allergy Symptoms
IRVINE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Cobalis Corp. (BULLETIN BOARD: CLSC) , announced today the final statistical analyses on allergy patient symptom scores collected during the first of two required FDA- approved Phase III Clinical Trials for the Company's anti-allergy medication, PreHistin(TM). The study was the largest of its kind, according to Lyndon Mansfield, MD, Cobalis' senior medical advisor, and successfully concludes one of the most important milestones towards gaining FDA ...